- Home
- KPLT vs AGEN Comparison
KPLT vs AGEN Comparison
Compare KPLT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- AGEN
- Stock Information
- Founded
- KPLT 2012
- AGEN 1994
- Country
- KPLT United States
- AGEN United States
- Employees
- KPLT N/A
- AGEN N/A
- Industry
- KPLT Diversified Commercial Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KPLT Consumer Discretionary
- AGEN Health Care
- Exchange
- KPLT Nasdaq
- AGEN Nasdaq
- Market Cap
- KPLT 35.6M
- AGEN 38.1M
- IPO Year
- KPLT N/A
- AGEN 2000
- Fundamental
- Price
- KPLT $7.60
- AGEN $2.83
- Analyst Decision
- KPLT Hold
- AGEN Buy
- Analyst Count
- KPLT 2
- AGEN 4
- Target Price
- KPLT $12.00
- AGEN $8.00
- AVG Volume (30 Days)
- KPLT 42.7K
- AGEN 742.0K
- Earning Date
- KPLT 05-14-2025
- AGEN 05-06-2025
- Dividend Yield
- KPLT N/A
- AGEN N/A
- EPS Growth
- KPLT N/A
- AGEN N/A
- EPS
- KPLT N/A
- AGEN N/A
- Revenue
- KPLT $247,194,000.00
- AGEN $103,463,000.00
- Revenue This Year
- KPLT $20.12
- AGEN $4.03
- Revenue Next Year
- KPLT $13.19
- AGEN $5.57
- P/E Ratio
- KPLT N/A
- AGEN N/A
- Revenue Growth
- KPLT 11.56
- AGEN N/A
- 52 Week Low
- KPLT $5.08
- AGEN $1.38
- 52 Week High
- KPLT $23.54
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- KPLT 38.06
- AGEN 71.19
- Support Level
- KPLT $7.18
- AGEN $1.60
- Resistance Level
- KPLT $8.12
- AGEN $3.40
- Average True Range (ATR)
- KPLT 0.75
- AGEN 0.32
- MACD
- KPLT -0.06
- AGEN 0.18
- Stochastic Oscillator
- KPLT 23.68
- AGEN 71.29
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).